AbbVie Inc (NYSE:ABBV)

57.27
Delayed Data
As of Mar 26
 -0.95 / -1.63%
Today’s Change
45.50
Today|||52-Week Range
70.76
-12.48%
Year-to-Date
Biotechs Need to Rest
5:24am / TheStreet.com
Pharmacyclics' Imbruvica Encourages in a Phase III Study - Analyst Blog
Mar 17 / Zacks.com
Drugs companies unite to mine genetic data
Mar 25 / FT.com
AbbVie to Buy Pharmacyclics: Biotech ETFs to Watch - ETF News And Commentary
Mar 17 / Zacks.com
Backing Away From Biotechs
Mar 25 / TheStreet.com
Pharma Stock Outlook: Let's Make a Deal - Industry Outlook
Mar 17 / Zacks.com
4 Top-Ranked Health Care ETFs for a Healthy Portfolio - ETF News And Commentary
Mar 25 / Zacks.com
Pharma Stock Outlook: Let's Make a Deal - Zacks Analyst Interviews
Mar 17 / Zacks.com
Biotech Stock Roundup: Biogen Soars on Alzheimer's Data, Gilead HCV Drugs Label Updat...
Mar 25 / Zacks.com
3 Stocks Benefiting From Jaw-Dropping Growth in Specialty Drug Spending
Mar 17 / MotleyFool.com
11 Promising New Drugs Expected to Make Billions in Sales
Mar 23 / TheStreet.com
The $136 Billion Cost of Hepatitis C Treatment
Mar 16 / MotleyFool.com
Pharmacyclics chief to receive $3.6bn from takeover
Mar 23 / FT.com
Is This Number the Scariest Healthcare Statistic Out There?
Mar 15 / MotleyFool.com
This Market Could Grow 6250% in 10 Years
Mar 23 / MotleyFool.com
Should Gilead Sciences Inc.bs Slowing Growth Concern Investors?
Mar 15 / MotleyFool.com
Better Dividend Stock: AbbVie or Gilead Sciences, Inc.?
Mar 23 / MotleyFool.com
Bristol-Myers Seeks Daclatasvir Approval in the U.S. - Analyst Blog
Mar 13 / Zacks.com
3 Things You Need to Know About Achillion Pharmaceuticals Inc.
Mar 22 / MotleyFool.com
Going the extra mile to win a B#21bn deal
Mar 06 / FT.com
Confessions of a Value Investor Stuck in a High-Growth Industry
Mar 22 / MotleyFool.com
AbbVie wins three-way fight over Pharmacyclics
Mar 05 / FT.com
Dividend Stocks: 2 to Avoid, 1 to Buy
Mar 21 / MotleyFool.com
AbbVie joins the pharma chain reaction
Mar 05 / FT.com
Drug Spending Is Soaring: 3 Takeaways You Can't Miss
Mar 21 / MotleyFool.com
Vertex climbs on drug approval hopes
Mar 05 / FT.com
Celgene's Data on Crohn's Disease Candidate Published - Analyst Blog
Mar 19 / Zacks.com
Centerview builds record on pharma deals
Mar 05 / FT.com
Aldeyra Initiates Phase II Sjogren-Larsson Syndrome Study - Analyst Blog
Mar 19 / Zacks.com
Abbvie/Pharmacyclics: pay to play
Mar 05 / FT.com
Biotech Stock Roundup: Amgen & Regeneron Shine at ACC, Nektar Drug Disappoints - Anal...
Mar 18 / Zacks.com
Q&A - why Abbvie had to strike $21bn Pharmacyclics deal
Mar 05 / FT.com
Why I'm Not Giving Up on This Tiny Biotech Stock (Yet)
Mar 18 / MotleyFool.com
Stocks: 5 things to know before the open
Mar 05 / CNNMoney.com

To view my watchlist

Not a member yet?

Sign up now for a free account